Health and Human Services Secretary Robert F. Kennedy Jr. earlier this month announced the cancellation of nearly $500 million in federal grants and contracts tied to mRNA vaccine development and launched a new vaccine safety task force.
The initiative, according to Kennedy, is aimed at addressing decades of alleged violations of the National Childhood Vaccine Injury Act.
💥 HUGE: HHS Reinstates Task Force on Safer Childhood Vaccines in Response to Lawsuit Funded by Children’s Health Defense
— Children’s Health Defense (@ChildrensHD) August 15, 2025
“We are grateful to @SecKennedy for fulfilling his duty under the 1986 National Childhood Vaccine Injury Act. It took nearly 30 years for HHS to do this, but… pic.twitter.com/12QyBMz078
The announcement was met with sharp criticism from many outlets, but new data has since emerged raising further questions about the safety and effectiveness of COVID-19 mRNA boosters.
A recently published study from Switzerland examined the health outcomes of 1,745 healthcare workers across 2023 and 2024. The research, published in Communications Medicine, a peer-reviewed Nature journal, found that employees who received COVID-19 boosters were more likely to report influenza-like symptoms and take sick leave compared to those who had not.
This is an interesting paper which looks well made
— Jean Fisch (@Jean__Fisch) August 15, 2025
They followed young mostly healthy HCW whose last dose of c19 vax was >1yr before
What they found is that staff with more doses had more days off sick and covid like events vs unvaxedhttps://t.co/2FmfzVVKwh
Association of SARS-CoV-2 vaccination status with risk of influenza-like illness and loss of workdays in he… by Red Voice News
The study, conducted by the SURPRISE+ Study Group, also found that individuals who received seasonal flu vaccines during the same time frame were less likely to report illness.
COVID-19 testing had largely been phased out by the study period, leaving symptom reporting and leave records as the primary measurements.
The Swiss findings echo research from the Cleveland Clinic in 2022, which tracked more than 51,000 employees and found “association of increased risk of COVID-19 with higher numbers of prior [mRNA] vaccine doses.”
Both studies suggest that, particularly for healthy young and middle-aged individuals, repeated boosters may not deliver the expected benefit and could even increase the short-term risk of illness.
The Swiss team concluded that “COVID-19 boosters may not offer clear short-term benefits in a post-pandemic setting, and may even increase short-term illness risk.”
They cautioned that routine boosting of healthy individuals may not meet the basic risk-benefit threshold, recommending further study.
Former New York Times pharmaceutical industry reporter Alex Berenson, writing about the study, noted its methodological strengths compared to earlier work, including careful matching of participants with comorbidities and detailed vaccination timelines.
He pointed out that while the study found the heightened risk of infection diminished over time, that pattern suggested the shots themselves—not statistical bias—were responsible for the increased illness rates.
The findings arrive as the government and medical community continue to debate the future of mRNA vaccine technology.
Just prior to the COVID-19 pandemic, leading public health officials openly discussed the challenges of introducing new vaccine platforms.
At a 2019 Milken Institute health summit, Dr. Anthony Fauci spoke about the lengthy trial process required for new vaccines, acknowledging that under normal circumstances, approvals could take a decade.
Rick Bright, then the head of HHS’s Biomedical Advanced Research and Development Authority, suggested that a disruptive outbreak could speed adoption by bypassing regulatory hurdles.
October 29th, 2019
— Champagne Joshi (@JoshWalkos) November 4, 2023
Milken Institute: The Future of Health Summit
Anthony Fauci & Rick Bright discuss a “Universal Flu Vaccine” and a hypothetical scenario where a novel virus emerges from China.
Just over 4 months prior to that actually happening and 11 days after Event 201… pic.twitter.com/F4ryF0InQp
Months later, the COVID-19 pandemic emerged, leading to the rapid development and deployment of mRNA vaccines under emergency authorization.
The standard long-term approval processes were replaced with accelerated timelines in response to the public health emergency.
The debate over the safety and long-term effectiveness of those vaccines has continued.
Supporters have maintained that mRNA technology saved millions of lives during the pandemic, while critics point to growing evidence of unintended risks and insufficient long-term data.
The new Swiss study adds weight to concerns that repeated boosters may not align with the public health benefits initially promised.
Kennedy’s decision to halt nearly half a billion dollars in federal support for mRNA research and to establish a vaccine safety task force comes in the context of this ongoing debate.
The task force is expected to review historical compliance with federal vaccine safety laws and assess future development protocols.
As discussions continue, the data from Switzerland and earlier findings from the Cleveland Clinic are likely to play a role in shaping both scientific and policy debates.
While officials in Washington, including Kennedy, pursue a reassessment of vaccine oversight, the controversy underscores the broader demand for transparency and accountability in public health decision-making.
